Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. März 2026 08:00 ET | Quelle: Amphista Therapeutics

Amphista Therapeutics announces three presentations at the American Association for Cancer Research Annual Meeting on its next-generation Targeted Glue™ degrader programs

Cambridge, UK, 23rd March 2026 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces three...
23. März 2026 03:00 ET | Quelle: Amphista Therapeutics

Amphista Therapeutics announces three presentations at the American Association for Cancer Research Annual Meeting on its next-generation Targeted Glue™ degrader programs

Cambridge, UK, 23rd March 2026 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces three...
08. Februar 2026 21:43 ET | Quelle: InnoCare Pharma

InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China

ICP-538 is the first VAV1 degrader approved to enter clinical trials in China and the second globally.